Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
During the review, the committee will likely consider: The extensive body of published research on GHK-Cu (decades of studies) Safety data for both injectable and topical routes The clinical rationale for copper peptide therapy in anti-aging and wound healing Quality control considerations for compounding GHK-Cu formulations Public comments from patients, dermatologists, anti-aging practitioners, and pharmacies Given GHK-Cu's long history of use and substantial research base, many in the peptide therapy community are cautiously optimistic about a positive PCAC recommendation particularly for the topical route
Peptide Therapy Adults Over 60: Who Is and Is Not a Candidate Strong Candidates Adults 60+ with documented low IGF-1 on serum testing Individuals with sarcopenia confirmed by DEXA or functional testing Active seniors experiencing delayed recovery, poor sleep, and reduced energy not explained by other pathology Adults managing visceral obesity with inadequate response to diet and exercise Individuals already on andropause or menopause hormone therapy who want adjunctive metabolic support Poor Candidates or Contraindicated Any history of active cancer (especially hormone-sensitive: prostate, breast, colon) Uncontrolled diabetes (HbA1c above 8.5%) Severe cardiac or renal impairment Active intracranial pathology (GH secretagogues stimulate pituitary
Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
Chen J, Li X, Ge C, Min J, Wang F
Nucleus undergoing lysis, not pyknosis
US$ 25.69
US$ 27.23
US$ 27.69
